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Outcomes research seeks to identify effective
evidence-based methods of providing the best
medical care. While randomized clinical trials
(RCT) usually provide the clearest answers, they
are often not done or not practicable. More than a
decade after the introduction of calcium channel
blockers and angiotensin converting enzyme
(ACE) inhibitors, clinical trial data about their
effect on major disease endpoints in patients with
hypertension are still not available. The primary
alternatives are the use of randomi/ed trials that
include Surrogate endpoints, such äs level of
blood pressure or extent of carotid atherosclerosis,
and the use of observational studies that include
major disease endpoints. Both approaches, their
strengths and limitations, are discussed in detail.
The possibility of residual confounding limits the
strength of inferences that can be drawn front
observational studies. Similarly, the possibility of
important drug effects, other than those involving
the Surrogate endpoint, limits the inferences that
can be drawn from randomized trials that rely
solely on Surrogate outcomes äs guides to therapy.
In the absence of evidence from large clinical
trials that include major disease endpoints,
treatment decisions and guidelines need to
synthesize the best available Information from a
variety of sources. Consistency of findings across
various study designs, outcomes, and populations
is critical to the practice of evidence-based
medicine and the effort to maximize the health
benefits of antihypertensive therapies. Am
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High blood pressure causes a variety ofclinical events, including stroke, myocar-dial infarction, "and congestive heart fail-ure. The primary goal of antihypertensive
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tion that it is not practicable to evaluate all of them
in large clinical trials.
The two principal alternative strategies are the use
of Surrogate endpoints in small short-term random-
ized clinical trials and the use of major disease end-
points in observational studies. We consider both ap-
proaches in this article. In the first part, we inquire
whether Surrogate endpoints, such äs level of blood
pressure, in randomized clinical trials are valid prox-
ies for major disease endpoints. In the second, we
examine the conditions under which observational
studies, such äs case-control studies, can provide
valid estimates of the risk or benefit of a therapy.
The purpose of this article is to provide an overview
of the strengths, limitations, and implications of the
evidence provided by studies that use various study
designs and outcomes. The Integration of Information
from these sources helps to enhance the quality of
the clinical decision-making process and to assure the
development of practice guidelines that rely on the
best available evidence.
SURROGATE ENDPOINTS IN CLINICAL
TRIALS
The logic of Surrogate endpoints seems compelling:
high blood pressure causes morbidity and mortality;
a drug therapy reduces the level of blood pressure;
thus the drug therapy reduces the risk of morbidity
and mortality. Surrogate endpoints may include not
only physiologic measures, such äs blood pressure,
but also measures of subclinical disease, such äs left
ventricular mass, or carotid or coronary atherosclero-
sis äs assessed by echocardiography, ultrasonogra-
phy, or angiography. The Treatment of Mild Hyper-
tension Study,1 for example, is a 4 year prospective
clinical trial that randomized participants to placebo
or one of four antihypertensive agents, and the end-
points included not only measures of compliance and
levels of blood pressure, but also electrocardiograms,
ambulatory electrocardiograms, and echocardiogra-
phy. Because these measures of subclinical disease are
themselves powerful risk factors for the major clinical
events, they are particularly appealing äs Surrogate
endpoints. In general, clinical trials using these con-
tinuous Surrogate endpoints can be rnuch smaller and
shorter than trials using major clinical events äs the
primary outcome.2 This economic advantage is worth
pursuing, of course, only if Surrogate endpoints serve
äs valid proxies for major disease endpoints in clinical
trials of antihypertensive therapies.
In order to make a definitive treatment decision
from a randomized clinical trial using a Surrogate
endpoint, a test of the null hypothesis of no treatment
effect based on the Surrogate endpoint should also be
a valid test of the corresponding null hypothesis
based on the true clinical endpoint. This correspon-
dence will occur if the Surrogate endpoint is predica-
tive of the true endpoint and the Surrogate fully cap-
tures the effect of treatment on the true clinical end-
point.3 Most Surrogate endpoints are selected because
they have been demonstrated to be strong predictors
for the occurrence of the clinical outcome in observa-
tional studies—namely, because they satisfy the first
condition. All antihypertension therapies have multi-
ple effects, some of which may not be mediated
through a particular Surrogate endpoint. Under these
circumstances, the second condition is rarely satisfied.
As a result, the use of evidence from Surrogate end-
points to infer the effects on long-term clinical out-
comes can produce highly misleading conclusions.
Though summarized only in Conference reports,
several recent randomized clinical trials in hyperten-
sion raise questions about the validity of Surrogate
endpoints in hypertension trials.4·5 In one clinical trial
from the Evaluation Group of Long-Term Antihyper-
tensive Treatment (GLANT) in Japan,5 hypertensive
patients were randomized to a calcium channel
blocker, either nifedipine or manidipine (n = 1017),
or to the angiotensin converting enzyme (ACE) inhib-
itor delapril (n = 1025), and followed for l year.
Blood pressure reduction was greater in subjects tak-
ing the calcium channel blocker. Despite this effect
on level of blood pressure, subjects treated with the
calcium-channel blocker had a significantly higher in-
cidence of cerebrovascular events than the patients
randomized to treatment with an ACE Inhibitor (risk
ratio [RR] = 3.0, 95% confidence interval [CI] = 1.1
to 8.3, P = .02). These clinical trial data ülustrate the
point that because drugs have multiple effects, the
use of blood pressure may not be adequate äs a Surro-
gate for the effect of antihypertensive therapies on
major disease endpoints.
In the Multicenter Isradipine Diuretic Atherosclero-
sis Study (MIDAS), hypertensive patients with early
carotid atherosclerosis were randomized to isradipine
(2.5 to 5.0 mg twice a day) or hydrochlorothiazide
(12.5 to 25.0 mg twice a day) and followed for 3 years
with serial carotid ultrasound examinations.6 While
the reduction in systolic blood pressure was larger
among those randomized to hydrochlorothiazide, the
reduction in diastolic blood pressure was almost iden-
tical in the two groups over 3 years. The primary out-
come was subclinical atherosclerosis, and long-term
progression was small and similar in both groups.4
Yet major vascular events were more common among
those randomized to isradipine (25 [4.9%] of 442)
than among those randomized to hydrochlorothiazide
(14 [3.3%] of 441; RR = 1.78, 95% CI = 0.94 to 3.38;
P = .07). Despite the fact that this calcium channel
blocker is supposed to have antianginal properties,
hospitalization for angina was almost four times more
common among subjects randomized to isradipine
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(RR = 3.66; 95% CI = 1.02 to 13.0; P < .05). In this
randomized trial, while the effect on the Surrogate
endpoint was nil, low-dose diuretic therapy appeared
to reduce the occurrence of major disease endpoints
better than the calcium channel blocker.
The International Nifedipine Trial on Antiathero-
sclerotic Therapy (INTACT) randomized 425 subjects
with mild corqnary atherosclerosis to short-acting
nifedipine or placebo.7 While participants in the study
did not necessarily have high blood pressure, the pri-
mary outcome was a Surrogate endpoint—the devel-
opment of new coronary lesions over a 3 year period.
Indeed, the use of nifedipine significantly reduced the
average number of new coronary lesions per patient
(0.82 for placebo v 0.59 for nifedipine, P = .03). But
there were 12 deaths among subjects randomized to
nifedipine compared with only two deaths among
subjects randomized to placebo. The RR for mortality
was 5.92 (95% CI = 1.34 to 26.2; P = .008). In INTACT,
the findings for subclinical and clinical endpoints
were both statistically significant. While the subclini-
cal Surrogate endpoint favored nifedipine, one of the
most clinically relevant endpoints, total mortality, fa-
vored placebo.
The most likely explanations for the disparity be-
tween the results for the Surrogate and the major dis-
ease endpoints are l) the fact that drugs have multiple
effects, some beneficial and some potentially harmful;
or 2) for a variety of reasons, either genetic or environ-
mental, some patients may be particularly susceptible
to certain drug effects compared to others. Because
these studies were well-conducted randomized clini-
cal trials, the findings for both the Surrogate endpoint
and the clinical endpoint are likely to be valid esti-
mates of the drug effect on the respective outcomes.
But since calcium channel blockers are powerful car-
diovascular agents that have multiple effects, it is not
possible to generalize, for instance, from a blood pres-
sure lowering effect to an effect on the risk of coronary
or cerebrovascular events. There are other recent ex-
amples of the failure of Surrogate endpoints in cardio-
vascular medicine: l Xtheuse of suppression of prema-
ture ventricular contractions by antiarrhythmic agents
äs a proxy for the incidence of sudden death among
postmyocardial infarction patients;8'9 2) the use of cho-
lesterol lowering by clofibrate äs a proxy for total mor-
tality;10 and 3) the use of oral milrinone to improve
hemodynamics äs a proxy for total mortality.11'12
As proxies for major disease endpoints, the level of
blood pressure in GLANT and the change in carotid
atherosclerosis in MIDAS were clearly inadequate or
partially misleading. While randomized controlled clin-
ical trials are appropriately regarded äs the gold Stan-
dard of evidence, the use of clinical trials alone does
not assure proper inference. The choice of outcome is
critical. The findings from GLANT illustrate the limita-
tions of drawing inferences from results based on the
Surrogate endpoints: interpretations based on level of
blood pressure control and risk of cerebrovascular
events would be diametrically opposed in this case. We
might revise the syllogism with which we started this
section in the following way: all drugs have multiple
effects; a single Surrogate endpoint is likely to measure
only a subset of those effects; therefore, studies using
Surrogate endpoints may be inadequate or misleading
äs a basis for the choice of a therapy.
MAJOR DISEASE ENDPOINTS
While the choice of the outcome is obviously critical,
studies that examine drug effects on major disease
endpoints are often lengthy and expensive to conduct
well. At the same time, the number of potentially eval-
uable antihypertensive agents is exceedingly large, es-
pecially if there are clinically important differences
among the various formulations of specific drugs or
among the various doses of those formulations. It is
simply not practicable to evaluate all antihypertensive
drugs, doses, and formulations in large endpoint tri-
als. The newest agents also tend to be the least well
evaluated.
One alternative to large long-term clinical trials is
the use of metaanalysis to combine the results from
multiple small short-term clinical trials. Metaanalysis
is a tool for the quantitative review of existing data.13~17
In metaanalysis, the individual clinical trials serve äs
the unit of analysis, and the within-trial estimates of
effect are preserved and summed across studies. Dose-
response analyses are also possible.15'18 Metaanalysis
is, however, subject to some of the same potential bi-
ases äs observational studies. For instance, lack of in-
formation from unpublished studies and incomplete
reporting of events in published studies may introduce
bias. A major drawback of metaanalysis is the inability
to evaluate new therapies. Even combining the end-
point data from several small trials designed to assess
the effect of a new drug or formulation on the level
of blood pressure would in general lack adequate
power to assess major disease endpoints.
The other major alternatives to large long-term ran-
domized trials are an observational studies, such äs the
cohort or case-control study.19"21 With these designs, it
is possible to use major disease endpoints, such äs
stroke or myocardial infarction, äs the outcome of inter-
est. Compared with randomized clinical trials, they are
efficient and relatively inexpensive. These study de-
signs are also capable of evaluating the effects of current
practice patterns on health.
In almost all respects, the use of observational studies
to evaluate the efficacy or safety of therapies is similar
to their use in the study of etiology. For case-control
studies, the essential design features include, for in-
stance, the complete ascertainment of cases from a de-
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fined population, the use of controls who reflect the
exposures sustained by the underlying population from
which the cases arose,22"24 and the comparable assess-
ment of exposures and covariates in cases and controls
alike.19·20 The fundamental difference is simply that the
validity of an observational study of a therapy depends
on the ability to control not only for the traditional risk
factors that are'associated with the outcome of interest,
but also for the clinical factors that may lead physicians
to use particular therapies for particular patients. In
other words, observational studies of the safety or effi-
cacy of a therapy pose this one additional difficulty,
which is the possibility of confounding by indication
or contraindication.25
For example, an antihypertensive agent, such äs an
ACE inhibitor, may be preferentially used in patients
with diabetes mellitus. Since diabetes mellitus is also a
risk factor for myocardial infarction, an observational
study may find spuriously, due to confounding, that
compared with diuretics, ACE inhibitors appear to in-
crease the risk of myocardial infarction. Similarly, ß-
blockers are indicated for the treatment of angina äs
well äs hypertension. Since angina is a risk factor for
myocardial infarction, an observational study may find
that compared with diuretics, the use of /3-blockers ap-
pears to increase the risk of myocardial infarction. Ob-
servational studies of therapeutic efficacy that seek to
control for confounding by indication often require a
detailed knowledge of how the therapies under study
are used in clinical practice and of how the use of those
therapies may have changed over the time course of
the study.
The approaches to handling confounding by indica-
tion—restriction, matching, stratification, and multi-
variate analysis—are the same äs the approaches to
handling other potential confounding factors in obser-
vational studies. In the ACE inhibitor example, it is
important initially to stratify the analysis on the pres-
ence or absence of diabetes mellitus. If the association
between drug use and myocardial infarction is similar
in both strata, then it is reasonable to combine the esti-
mates and adjust for diabetes mellitus. Within each stra-
tum, a fairer comparison of the effects of the alternative
drugs is possible. If the associations differ according to
the presence or absence of diabetes mellitus, then it
may be reasonable to present separate estimates for
each group. An alternative is restriction—simply to ex-
clude all subjects with any clinical evidence of diabetes
mellitus from the analysis. In other words, confounding
by indication can be recognized and dealt with by the
same methods that we use to deal with confounding
from more traditional sources, such äs demographic
factors.
For some therapies, it may be difficult or impossible
to use observational studies to evaluate their efficacy
and safety. Pentoxyfylline, for example, is the only
approved drug therapy for peripheral vascular dis-
ease. With surgery äs the alternative therapy, pentoxy-
fylline tends to be used in practice either in patients
with mild disease or in patients whose surgical risk
is too high. Under these circumstances, the choice of
medical versus surgical therapy is strongly and com-
plexly confounded by severity of disease,26 and the
area of overlap, where either therapy is equally indi-
cated, may be small. For hypertension, on the other
hand, scores of comparable drugs are available, and
Variation in drug use depends in large part on physi-
cian practice style.27'28 These circumstances are pre-
cisely the ones in which a nonrandomized study of
effectiveness can be expected to have the greatest
validity.29
Of course, nonexperimental studies may give mis-
leading results.29 In several instances, including the
study of hypertensive therapies, however, observa-
tional studies have provided results comparable to
those of the randomized trials. In a metaanalysis of
randomized clinical trials comparing /3-blockers with
diuretics in middle-aged adults, Collins and colleagues
reported a slight advantage of /3-blockers in the preven-
tion of coronary heart disease.30 The RR was 0.94 (95%
CI = 0.78 to 1.10). Similarly, in a case-control study,31
the use of /?-blockers compared with other therapies,
principally high dose diuretics, was associated with a
small reduction in the risk of coronary heart disease in
patients with high blood pressure. The RR was 0.87
(95% CI = 0.62 to 1.21). These estimates of effect, 0.94
and 0.87, are similar.
The findings of observational studies can also com-
plement those of randomized controlled clinical trials.
In the large hypertension trials in middle-aged adults,
high doses of diuretics, the equivalent of 50 to 100 mg
of hydrochlorothiazide per day, were generally used,
and the reduction in the incidence of coronary disease
was less than expected from observational studies of
the association with level of blood pressure.30'32 The
recent trials in older adults often used low doses of
diuretics, the equivalent of 12.5 to 25 mg of hydrochlo-
rothiazide, sometimes in combination with potassium-
sparing agents.33"35 For diuretics, coronary heart dis-
ease risk was reduced by 21 %,36 which is within the
ränge of the expected reduction of 20% to 25%.32 From
the results of these clinical trials alone, it is not possible
to teil whether the difference between the two genera-
tions of large clinical trials is the result of patient age
or dose of the diuretic. The recent case-control study
by Siscovick and colleagues suggests that compared
with high dose diuretic therapy, low dose diuretic ther-
apy, with or without potassium-sparing agents, was
associated with a substantially reduced risk of primary
cardiac arrest—a finding that was present and similar
in magnitude in both the middle-aged and the older
adults.37 Importantly, observational studies have the
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ability to examine dose-response relationships that are
often not available in clinical trials.
The study of hypertension serves perhaps äs a
model of studies in which observational studies can
provide results comparable to randomized clinical tri-
als. In part because a large number of alternative ther-
apies are available and commonly used, antihyperten-
sive therapy is well suited to an outcome evaluation
by observational methods. In several case-control
studies,31·37'38 patient characteristics, such äs smoking,
diabetes mellitus, and cholesterol level, were only
weakly associated with the choice of therapy in clini-
cal practice. The high degree of similarity in treatment
regimens between controls with and without various
clinical characteristics not only minimizes the possi-
bility of important confounding by those characteris-
tics but also provides some assurance of the validity
of the adjusted comparisons.
Like clinical trials, observational studies of thera-
peutic efficacy and safety must be conducted well.
Even the best observational studies nonetheless have
important limitations. First, there may be unknown
or unmeasured confounding factors for which adjust-
ment is not possible. In observational studies of drug
therapies, these may include confounding by indica-
tion, in which the selection of antihypertensive treat-
ment by physicians and patients may introduce bias.
Secondly, measurement error in the assessment of the
presence or the severity of exposures or covariates
may result in bias or in incomplete adjustment and
residual confounding. Large clinical trials, which are
not subject to these limitations, are also important be-
cause they can assess the overall risk or benefit of a
therapy in terms of a variety of important cardiovas-
cular outcomes—not only a single case group, such
äs patients with myocardial infarction, but also for
the other important outcomes of stroke, congestive
heart failure, renal disease, and total mortality.
SYNTHESIS AND CLINICAL IMPLICATIONS
Ideally, practitioners would like to base clinical deci-
sions about antihypertensive therapy upon the results
of randomized clinical trials that include major dis-
ease endpoints. Currently, approval by the Food and
Drug Administration requires evidence of efficacy
measured solely in terms of the effect of antihyperten-
sive agents on a Surrogate endpoint—the level of
blood pressure. As a result, clinical trial data for the
long-term safety and efficacy of the newer agents—
calcium-channel blockers, α-blockers, and ACE Inhib-
itors—are lacking in patients with high blood pres-
sure. In the absence of Information from major clinical
trials, clinicians still need to make treatment decisions
based upon the best available scientific evidence. In-
ferences from randomized trials that evaluate thera-
pies in terms of their effects on blood pressure may
be limited. On the other hand, it is difficult to exclude
the possibility of confounding in observational stud-
ies. These limitations are complementary.
Treatment decisions and guidelines need to synthe-
size the best available Information from a variety of
sources. In the end, consistency of findings across var-
ious studies, designs, outcomes, and populations is
critical to the conduct of evidence-based medicine and
the effort to maximize the health benefits of antihyper-
tensive therapies.
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